Research Topics
Species | Christopher W RyanSummaryAffiliation: Oregon Health and Science University Country: USA Publications
| Collaborators
|
Detail Information
Publications
A phase II study of tasisulam sodium (LY573636 sodium) as second-line or third-line treatment for patients with unresectable or metastatic soft tissue sarcomaChristopher W Ryan
Section of Hematology Oncology, Oregon Health and Science University Knight Cancer Institute, Portland, OR, USA
Invest New Drugs 31:145-51. 2013..Secondary objectives included objective response rate (ORR), clinical benefit rate (CBR), overall survival (OS), pharmacokinetics, and safety...
A phase I/II dose-escalation study of exisulind and docetaxel in patients with hormone-refractory prostate cancerChristopher W Ryan
Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR 97239 3098, USA
BJU Int 95:963-8. 2005....- Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapyChristopher W Ryan
Cancer Institute, Oregon Health and Science University, Portland, Oregon 97239, USA
Urology 70:122-6. 2007..We sought to examine the impact of ADT and lifestyle variables on BMD in 120 patients with prostate cancer without bone metastases entering a randomized clinical trial... - Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acidChristopher W Ryan
Division of Hematology and Medical Oncology, Oregon Health and Science University, 3303 SW Bond Avenue, Portland, OR 97239, USA
BJU Int 100:70-5. 2007.... - Histologic response of dose-intense chemotherapy with preoperative hypofractionated radiotherapy for patients with high-risk soft tissue sarcomasChristopher W Ryan
Department of Medicine, Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR 97239, USA
Cancer 112:2432-9. 2008..The authors studied a dose-intense regimen of epirubicin and ifosfamide with hypofractionated preoperative radiotherapy for high-risk soft tissue sarcomas. The primary objective was estimation of the rate of >or=95% pathologic necrosis... - A phase II trial of O6-benzylguanine and carmustine in patients with advanced soft tissue sarcomaChristopher W Ryan
Division of Hematology and Medical Oncology, Oregon Health and Science University, 3181 SW Sam Jackson Park Rd CR145, Portland, OR 97239, USA
Cancer Chemother Pharmacol 58:634-9. 2006..We performed a phase II study to explore the activity of O6-BG in combination with BCNU in patients with advanced soft tissue sarcoma... - Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancerChristopher W Ryan
Division of Hematology Oncology, Oregon Health and Science University, 3181 Southwest Sam Jackson Park Road, Portland, OR 97239, USA
J Urol 176:972-8; discussion 978. 2006..We evaluated the effect of zoledronic acid initiated subsequent to androgen deprivation therapy on bone mineral density and biochemical markers of bone turnover... - Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignanciesChristopher W Ryan
Section of Hematology Oncology, Department of Medicine, Cancer Research Center, and Committee on Clinical Pharmacology and Pharmacogenomics, University of Chicago, Chicago, and Abbott Laboratories, Abbott Park, Illinois, USA
Clin Cancer Res 10:4406-11. 2004..This Phase I study sought to determine the toxicity and pharmacokinetics of daily atrasentan in a population of both female and male subjects with advanced malignancies... - A phase II study of everolimus in combination with imatinib for previously treated advanced renal carcinomaChristopher W Ryan
Oregon Health and Science University Knight Cancer Institute, Portland, OR 97239, USA
Invest New Drugs 29:374-9. 2011..The primary endpoint was estimation of the 3-month progression-free rate... - C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trialTomasz M Beer
Division of Hematology and Medical Oncology, Oregon Health and Sciences University, Portland, OR 97239, USA
Cancer 112:2377-83. 2008..The authors sought to determine whether specific blood proteins associated with inflammation predict for outcomes in men with metastatic androgen-independent prostate cancer (AIPC) who are initiating docetaxel-based chemotherapy... - Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT InvestigatorsTomasz M Beer
Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health and Science University, Portland, OR 97239, USA
J Clin Oncol 25:669-74. 2007..To compare the safety and activity of DN-101, a new high-dose oral formulation of calcitriol designed for cancer therapy, and docetaxel with placebo and docetaxel... - Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxelTomasz M Beer
Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon 97239, USA
Cancer 112:326-30. 2008..In the current study, the authors examined retreatment with the same regimen after a treatment holiday... - A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancerJoseph S Chan
Oregon Health and Science University, Portland, OR 97239, USA
BJU Int 102:1601-6. 2008..To evaluate the preliminary efficacy, safety, and impact on quality of life (QoL) of high-dose calcitriol (DN-101) combined with mitoxantrone and glucocorticoids in androgen-independent prostate cancer (AIPC)... - High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: a phase I/II studyNatasha M Tiffany
Division of Hematology and Medical Oncology, Oregon Health Sciences University and Portland Veterans Affairs Medical Center, Portland 97239, USA
J Urol 174:888-92. 2005..One of 11 patients (9%) treated with prior docetaxel met these criteria. CONCLUSIONS: High dose calcitriol may be safely added to docetaxel and estramustine administered on a 21-day schedule... - Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancerR Bruce Montgomery
Department of Medicine, Veterans Affairs Puget Sound Health Care System VAPSHCS, and University of Washington School of Medicine, Seattle, WA 98108, USA
Cancer 110:996-1002. 2007..The addition of diethylstilbestrol to docetaxel modified tubulin composition and improved the response of prostate cancer to chemotherapy in preclinical models. An attempt was made to recapitulate the observations in a clinical trial... - Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancerWalter M Stadler
University of Chicago, Illinois 60637, USA
J Urol 170:1141-5. 2003..To identify patient subgroups most likely to benefit and compare survival to that in previously described patient series long-term survival as a function of known and suspected prognostic variables was determined... - A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapyTomasz M Beer
Knight Cancer Institute, Oregon Health and Science University, 3303 SW Bond Ave, Portland, OR 97239, USA
Anticancer Drugs 21:433-8. 2010..The median time to progression was 4 weeks. In conclusion, this regimen of low-dose transdermal estradiol induction followed by PPX does not have activity in taxane pretreated patients with castration-resistant prostate cancer... 
Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology GrMichael C Heinrich
Division of Hematology Oncology, Department of Medicine and Cell and Developmental Biology, Portland Veterans Affairs Medical Center and Oregon Health and Science University Cancer Institute, Portland, OR 97239, USA
J Clin Oncol 26:5360-7. 2008..In previous studies, GIST genotype correlated with treatment outcome and optimal imatinib dosing...- Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium studyNancy B Davis
Section of Hematology/Oncology, University of Chicago Medical Center, 5841 S Maryland Avenue, MC 2115, Chicago, IL 60637, USA
J Clin Oncol 22:115-9. 2004..Insufficient biopsy and whole blood sample numbers preclude conclusions regarding proteasome inhibition within tumor. Further evaluation in this disease setting is not recommended... - Southwest Oncology Group phase II study of ispinesib in androgen-independent prostate cancer previously treated with taxanesTomasz M Beer
Oregon Health and Science University Cancer Institute, Portland, OR 97239, USA
Clin Genitourin Cancer 6:103-9. 2008..In this study, we sought to assess the efficacy of ispinesib, a mitotic kinesin spindle protein (KSP) inhibitor in androgen-independent prostate cancer progressing after docetaxel... - Testosterone loss and estradiol administration modify memory in menTomasz M Beer
Department of Medicine, Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon, USA
J Urol 175:130-5. 2006..We characterized the impact of androgen deprivation and of subsequent estradiol therapy on the long-term and working memory of patients with prostate cancer... - Southwest Oncology Group phase II study of irinotecan in patients with advanced transitional cell carcinoma of the urothelium that progressed after platinum-based chemotherapyTomasz M Beer
Oregon Health and Science University Cancer Institute, Portland, OR 97239, USA
Clin Genitourin Cancer 6:36-9. 2008..The purpose of this study was to characterize the activity and toxicity of irinotecan in metastatic platinum-refractory urothelial carcinoma... - Effects of transdermal estrogen on levels of lipids, lipase activity, and inflammatory markers in men with prostate cancerJonathan Q Purnell
Department of Medicine, Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland, OR 97239, USA
J Lipid Res 47:349-55. 2006..Compared with ADT, short-term TDE therapy of prostate cancer improves lipid levels without deterioration of CVD-associated inflammatory markers and may, on longer-term follow-up, improve CVD and mortality rates... - High dose calcitriol may reduce thrombosis in cancer patientsTomasz M Beer
Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR 97239, USA
Br J Haematol 135:392-4. 2006..In vitro and vitamin D receptor (VDR) knockout mouse studies predict that nanomolar concentrations of calcitriol may act as an antithrombotic agent. We report the first clinical observation that supports this hypothesis in humans... - Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology GroupChristopher W Ryan
Oregon Health and Science University, Portland, OR, USA
J Clin Oncol 25:3296-301. 2007..This phase II study evaluated the activity of combined treatment with interferon alfa-2b and sorafenib, a Raf and multiple receptor tyrosine kinase inhibitor, in patients with advanced renal carcinoma... - Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North AmericaWalter M Stadler
Department of Medicine, University of Chicago Medical Center, Chicago, Illinois
Cancer 116:1272-80. 2010..The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) program made sorafenib available to patients with advanced renal cell carcinoma (RCC) before regulatory approval... - A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinomaChristopher W Ryan
Department of Medicine, Section of Hematology Oncology, University of Chicago, Chicago, Illinois, USA
Cancer 94:2602-9. 2002.... - Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033Charles D Blanke
Oregon Health and Science University Cancer Institute, 3181 SW Sam Jackson Park Rd, L 586, Portland, OR 97239, USA
J Clin Oncol 26:626-32. 2008.... - A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancerChristopher W Ryan
Department of Medicine, Section of Hematology Oncology, University of Chicago MC2115, 5841S Maryland Ave, Chicago, IL 60637, USA
Cancer Chemother Pharmacol 50:1-5. 2002..The purpose of this study was to determine the maximum tolerated dose and toxicities of suramin when administered using a fixed dosing scheme on a once- or twice-monthly schedule... - Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) eraPeter C Wu
Department of Surgery, University of Chicago, 5841 S. Maryland Avenue, Chicago, IL 60637, USA
Surgery 134:656-65; discussion 665-6. 2003..The true efficacy of imatinib in this setting, as induction therapy or as an adjuvant treatment in patients with GIST, is unknown pending the completion of ongoing prospective trials... - A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancerWalter M Stadler
University of Chicago Phase II Consortium, University of Chicago, Section of Hematology Oncology, Chicago, Illinois 60637, USA
Clin Cancer Res 10:3365-70. 2004..In vitro assessment of SU5416 on PSA secretion was assessed in the LNCaP cell line. Baseline serum basic fibroblast growth factor and plasma vascular endothelial growth factor (VEGF) were explored as prognostic factors... - Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortiumJonathan E Rosenberg
Department of Medicine, University of California San Franscisco, Helen Diller Family Comprehensive Cancer Center, 1600 Divisadero St, Box 1711, San Francisco, CA 94115, USA
J Clin Oncol 27:2772-8. 2009..Mitoxantrone plus prednisone and ixabepilone each have modest activity as second-line chemotherapy in docetaxel-refractory castration-resistant prostate cancer (CRPC) patients. Clinical noncrossresistance was previously observed... - Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancerTomasz M Beer
Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health and Science University, Mail Code CR 145, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA
Cancer Chemother Pharmacol 59:581-7. 2007..DN-101 is a new, high-dose, oral formulation of calcitriol under investigation for the treatment of cancer. We sought to evaluate the tolerability and pharmacokinetics (PK) of weekly doses of DN-101 in patients with advanced cancer... - A phase II trial of UFT and leucovorin in women 65 years and older with advanced breast cancerSupriya Gupta
Department of Medicine, The University of Chicago, Chicago, Illinois, USA
Am J Clin Oncol 28:65-9. 2005..Although UFT/leucovorin had efficacy in 1 patient, toxicity in the patients over 70 years of age was increased. Careful evaluation of anticancer drug toxicity in very elderly patients is important as our population ages... - Phase II study of transdermal estradiol in androgen-independent prostate carcinomaLisa B Bland
Division of Urology, Oregon Health and Science University and Portland Veterans Affairs Medical Center, Portland, Oregon, 97239, USA
Cancer 103:717-23. 2005..CONCLUSIONS: In patients with APIC, TDE was well tolerated and produced a modest response rate, but was not associated with thromboembolic complications or clinically important changes in several coagulation factors... - Current clinical trials in renal cell carcinomaMitchell H Sokoloff
Department of Surgery, Section of Urologic Oncology, Division of Urology and Renal Transplantation, Portland, OR 97239 3098, USA
Urol Oncol 23:289-92. 2005..This review highlights several key trials currently available for patients with kidney cancer... - Overcoming autopsy barriers in pediatric cancer researchJennifer L Alabran
Pediatric Cancer Biology Program, Papé Family Pediatric Research Institute, Oregon Health and Science University, Portland, OR 97239 3098, USA
Pediatr Blood Cancer 60:204-9. 2013..The purpose of this study was to identify barriers to autopsies and develop guidelines for requesting autopsies for research purposes... - Patients presenting with CNS lesions. Case 2. Subdural presentation of recurrent breast cancerJ Lee Villano
Department of Medicine, University of Chicago, IL, USA
J Clin Oncol 21:4060-2. 2003 - Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot studyAdam S Kibel
Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri 63105, USA
J Urol 177:1777-81. 2007..Patients with adverse pathological features are at high risk for recurrence following radical prostatectomy. To improve outcomes in this population we performed a phase II study of adjuvant docetaxel in these high risk patients... - A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapyNancy B Davis
Division of Neoplastic Diseases and Related Disorders, Medical College of Wisconsin, Milwaukee, WI, USA
BJU Int 96:787-90. 2005..To determine the prostate-specific antigen (PSA) response and time to PSA or radiographic progression in men with prostate cancer refractory to bicalutamide and/or flutamide therapy... - The hazards of intermediate endpointsTomasz M Beer
Cancer 110:1877-9. 2007 - A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxelRobert W Ross
Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Cancer 112:521-6. 2008..The authors conducted a phase 2 trial of docetaxel plus carboplatin chemotherapy in this disease setting... - Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapyRon S Israeli
Staten Island Urological Research, Staten Island, New York, USA
J Urol 179:414-23. 2008..We reviewed the pathogenesis, diagnosis, prevalence, prevention and treatment of bone loss in patients with nonmetastatic prostate cancer receiving androgen deprivation therapy...